Functional exhaustion of CD8+ T cells has been well described in chronic viral infections and in cancer, but great heterogeneity exists evidenced by distinct different populations of PD-1+ CD8+ T cells that respond differently to anti-PD-1 treatment (Blackburn et al, 2008; Paley et al, 2012). This evidence concerns the gene CD8A and cancer.